First FDA-approved CAR-T Cell Therapy for Lymphoma to Be Available at City of Hope

October 18, 2017 | City of Hope

City of Hope will be the one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. FDA announced today is the first approved CAR-T therapy for adult patients for some types of non-Hodgkin lymphoma

Continue Reading

Preclinical CMV Vaccine Shows Promise

October 18, 2017 | Letisia Marquez

A group of researchers in City of Hope’s Department of Experimental Therapeutics and Cal Tech may be one step closer to developing the first CMV vaccine for commercial use.

New in OncoImmunology: Novel treatment for triple-negative breast cancer

September 25, 2017 | City of Hope

City of Hope doctors and scientists have published a study in OncoImmunology about a triple-negative breast cancer patient whose disease regressed rapidly when she took part in an experimental treatment that combines a p53 cancer vaccine, which was developed at City of Hope, and a drug that blocks a specific cancer-aiding protein.

California Stem Cell Agency Awards $4 million to Two City of Hope Scientists

July 14, 2017 | Katie Neith

Two City of Hope research programs are among 13 projects to recently receive funding from the California Institute of Regenerative Medicine’s Discovery Quest Awards Program.

Sunita Patel Leads Impressive Slate of Grant Awardees

July 7, 2017 | Samantha Bonar

Sunita Patel, Ph.D., a neuropsychologist in the Population Sciences and Supportive Care Medicine departments at City of Hope, has received a $1.22 million grant from the American Cancer Society to test a new approach toward preventing long-term chemotherapy-related cognitive side effects.

PD-L1 inhibition is 'effective and safe' in patients with relapsed or refractory Hodgkin lymphoma

June 29, 2017 | Katie Neith

Clinical trial results in positive outcomes for patients with relapsed or treatment-resistant disease. Hodgkin lymphoma is typically considered to be one of the most curable forms of cancer, but some with the disease relapse or find that their cancer is resistant to treatment. For patients like this, a fully human monoclonal antibody called avelumab has shown promising results in a phase 1 clinical trial for safety and efficacy.

Groundbreaking Stem Cell Study Ultimately Seeks a Cure for AIDS

June 20, 2017 | Samantha Bonar

Dan Rojas, 31, who has been living with HIV since 2011, is one of a handful of brave patients participating in a groundbreaking study at City of Hope that seeks a cure for AIDS.

New Study: Tracking Surgery Patients via FitBit

June 19, 2017 | Samantha Bonar

Tracking patients using wireless wrist monitors like Fitbits is a good way to evaluate their recovery after major surgery, according to new research published in JAMA Surgery by City of Hope’s Virginia Sun, Ph.D., R.N., an assistant professor in the Division of Nursing Research and Education.

Novel Regimen May Stop Graft-Versus-Host Disease

May 4, 2017 | Katie Neith

An international team of researchers led by City of Hope’s Defu Zeng believe they may have found a way to prevent graft-versus host disease following stem cell transplants without sacrificing the transplants’ ability to fight leukemia and lymphoma.

Load More